JP2022524974A5 - - Google Patents
Info
- Publication number
- JP2022524974A5 JP2022524974A5 JP2021552136A JP2021552136A JP2022524974A5 JP 2022524974 A5 JP2022524974 A5 JP 2022524974A5 JP 2021552136 A JP2021552136 A JP 2021552136A JP 2021552136 A JP2021552136 A JP 2021552136A JP 2022524974 A5 JP2022524974 A5 JP 2022524974A5
- Authority
- JP
- Japan
- Prior art keywords
- pharmaceutically acceptable
- stereoisomer
- solvate
- acceptable salt
- compound according
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
Applications Claiming Priority (9)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201962816698P | 2019-03-11 | 2019-03-11 | |
| US62/816,698 | 2019-03-11 | ||
| US201962835376P | 2019-04-17 | 2019-04-17 | |
| US62/835,376 | 2019-04-17 | ||
| US201962877741P | 2019-07-23 | 2019-07-23 | |
| US62/877,741 | 2019-07-23 | ||
| US201962931119P | 2019-11-05 | 2019-11-05 | |
| US62/931,119 | 2019-11-05 | ||
| PCT/US2020/021850 WO2020185755A1 (en) | 2019-03-11 | 2020-03-10 | Tyk2 inhibitors and uses thereof |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2022524974A JP2022524974A (ja) | 2022-05-11 |
| JP2022524974A5 true JP2022524974A5 (enExample) | 2023-03-20 |
| JP7586829B2 JP7586829B2 (ja) | 2024-11-19 |
Family
ID=72427699
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2021552136A Active JP7586829B2 (ja) | 2019-03-11 | 2020-03-10 | Ｔｙｋ２阻害剤およびその使用 |
Country Status (10)
| Country | Link |
|---|---|
| US (2) | US20220177486A1 (enExample) |
| EP (1) | EP3938369A4 (enExample) |
| JP (1) | JP7586829B2 (enExample) |
| KR (1) | KR102899985B1 (enExample) |
| CN (1) | CN113811534B (enExample) |
| AU (1) | AU2020239026B2 (enExample) |
| BR (1) | BR112021017996A2 (enExample) |
| CA (1) | CA3132632A1 (enExample) |
| IL (1) | IL286248B2 (enExample) |
| WO (1) | WO2020185755A1 (enExample) |
Families Citing this family (13)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP7631193B2 (ja) | 2018-10-22 | 2025-02-18 | アルミス インコーポレイテッド | Ｔｙｋ２阻害剤およびその使用 |
| CA3134814A1 (en) * | 2019-03-26 | 2020-10-01 | Ventyx Biosciences, Inc. | Tyk2 pseudokinase ligands |
| WO2020233645A1 (zh) | 2019-05-21 | 2020-11-26 | 浙江海正药业股份有限公司 | 大环类衍生物、及其制备方法和用途 |
| JP7635228B2 (ja) | 2019-11-08 | 2025-02-25 | ベンティックス バイオサイエンシーズ，インク． | Ｔｙｋ２偽キナーゼリガンド |
| EP4214215A1 (en) * | 2020-09-16 | 2023-07-26 | Alumis Inc. | Tyk2 inhibitors and uses thereof |
| CN114591351B (zh) * | 2020-12-03 | 2023-12-05 | 成都科岭源医药技术有限公司 | 一种多环化合物及其制备方法和用途 |
| EP4423086A1 (en) | 2021-10-25 | 2024-09-04 | Kymera Therapeutics, Inc. | Tyk2 degraders and uses thereof |
| CA3245808A1 (en) * | 2022-03-16 | 2023-09-21 | Alumis Inc. | TYK2 INHIBITORS AND THEIR USES |
| CN119487037A (zh) * | 2022-03-16 | 2025-02-18 | 阿鲁米斯股份有限公司 | Tyk2抑制剂及其用途 |
| WO2023208244A1 (zh) * | 2022-04-29 | 2023-11-02 | 南京明德新药研发有限公司 | 大环类化合物及其应用 |
| JP2026512838A (ja) * | 2023-03-31 | 2026-04-21 | 北京普祺医薬科技股▲分▼有限公司 | 大環化合物、医薬組成物及びその使用 |
| WO2024222807A1 (en) * | 2023-04-27 | 2024-10-31 | Hangzhou Highlightll Pharmaceutical Co., Ltd | Novel macrocyclic heteroaryl derivatives as kinase inhibitors |
| WO2025194074A1 (en) * | 2024-03-15 | 2025-09-18 | Neuron23, Inc. | Kinase modulators and methods of use thereof |
Family Cites Families (13)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US7517882B2 (en) * | 2006-09-18 | 2009-04-14 | Polaris Group | Protein kinase inhibitors |
| WO2013001310A1 (en) * | 2011-06-30 | 2013-01-03 | Centro Nacional De Investigaciones Oncológicas (Cnio) | Macrocyclic compounds and their use as cdk8 inhibitors |
| ES2702126T3 (es) * | 2013-12-10 | 2019-02-27 | Bristol Myers Squibb Co | Compuestos de imidazopiridazina útiles como moduladores de respuestas a IL-12, IL-23 y/o IFN alfa |
| ES2933350T3 (es) * | 2014-01-24 | 2023-02-06 | Turning Point Therapeutics Inc | Macrociclos de diarilo como moduladores de proteína quinasas |
| AU2016287568B2 (en) * | 2015-07-02 | 2020-08-20 | Turning Point Therapeutics, Inc. | Chiral diaryl macrocycles as modulators of protein kinases |
| US10479793B2 (en) * | 2015-11-18 | 2019-11-19 | Bristol-Myers Squibb Company | Imidazopyridazine compounds useful as modulators of IL-12, IL-23 and/or IFN alpha responses |
| JOP20190092A1 (ar) * | 2016-10-26 | 2019-04-25 | Array Biopharma Inc | عملية لتحضير مركبات بيرازولو[1، 5-a]بيريميدين وأملاح منها |
| JOP20190213A1 (ar) * | 2017-03-16 | 2019-09-16 | Array Biopharma Inc | مركبات حلقية ضخمة كمثبطات لكيناز ros1 |
| SI3658557T1 (sl) | 2017-07-28 | 2024-10-30 | Takeda Pharmaceutical Company Limited | Zaviralci TYK2 in njihova uporaba |
| CN111182903A (zh) * | 2017-07-28 | 2020-05-19 | 特普医药公司 | 巨环化合物及其用途 |
| CN109053682B (zh) * | 2018-07-27 | 2020-10-27 | 东南大学 | 一种tdo小分子抑制剂衍生物及其抗肿瘤偶联物和制备方法 |
| CA3134814A1 (en) * | 2019-03-26 | 2020-10-01 | Ventyx Biosciences, Inc. | Tyk2 pseudokinase ligands |
| JP7635228B2 (ja) * | 2019-11-08 | 2025-02-25 | ベンティックス バイオサイエンシーズ，インク． | Ｔｙｋ２偽キナーゼリガンド |
-
2020
- 2020-03-10 CA CA3132632A patent/CA3132632A1/en active Pending
- 2020-03-10 US US17/438,329 patent/US20220177486A1/en not_active Abandoned
- 2020-03-10 EP EP20769748.3A patent/EP3938369A4/en active Pending
- 2020-03-10 BR BR112021017996A patent/BR112021017996A2/pt unknown
- 2020-03-10 AU AU2020239026A patent/AU2020239026B2/en active Active
- 2020-03-10 WO PCT/US2020/021850 patent/WO2020185755A1/en not_active Ceased
- 2020-03-10 IL IL286248A patent/IL286248B2/en unknown
- 2020-03-10 JP JP2021552136A patent/JP7586829B2/ja active Active
- 2020-03-10 CN CN202080034800.9A patent/CN113811534B/zh active Active
- 2020-03-10 KR KR1020217032541A patent/KR102899985B1/ko active Active
-
2025
- 2025-05-20 US US19/213,418 patent/US20250276977A1/en active Pending